AstraZeneca said the job cuts are a result of increased efficiencies following a multimillion-dollar upgrade at its plant in Macclesfield. Now, fewer employees are needed to maintain operations.
GMB Union, a local union representing the U.K. workers, called the decision a “hammer blow for manufacturing,” according to the report.
The campus in the U.K. where the job cuts will occur produces small-molecule drugs.
More articles on pharmacy:
10 hospitals seeking pharmacy leadership
Patent protection clause is latest stumbling block for revised NAFTA
Dr. Reddy’s legal win expected to lower cost of opioid addiction treatment
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
